Preclinical data suggest that HER3 overexpression increases sensitivity to TKIs such that sensitivity towards gefitinib was only seen in NSCLC cell lines with increased expression of HER3 (Engelman et al, 2005). Here, ERBB3 is linked to non-small cell lung carcinoma.